Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT

Leukemia

Volumn 31, Issue 10, 2017, Pages 2161-2171

  Neuenhahn, M ^a,b   Albrecht, J ^a   Odendahl, M ^c   Schlott, F ^a   Dossinger G ^a   Schiemann, M ^a   Lakshmipathi, S ^a   Martin, K ^a   Bunjes, D ^d   Harsdorf, S ^d   Weissinger, E M ^e   Menzel, H ^f   Verbeek, M ^g   Uharek, L ^h   Kroger N ⁱ   Wagner, E ^j   Kobbe, G ^k   Schroeder, T ^k   Schmitt, M ^l   Held, G ^m   Herr, W ⁿ   Germeroth, L ^o   Bonig, H ^p   Tonn, T ^c,q,r   Einsele, H ^s   Busch, D H ^a,b   Grigoleit, G U ^s   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DZIF National Centre for Infection Research   (Germany)

^c Red Cross Donor Service Sachsen   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f St Franziskus Hospital   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m SAARLAND UNIVERSITY   (Germany)

ⁿ UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^o Stage Cell Therapeutics   (Germany)

^p GOETHE UNIVERSITY   (Germany)

^q DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^r CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^s UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOFOS; FLUDARABINE; HLA ANTIGEN; MELPHALAN; OKT 3; PREDNISOLONE; THIOTEPA; THYMOCYTE ANTIBODY; ANTIVIRUS AGENT; T LYMPHOCYTE RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELL EXPANSION; CELL TRANSFER; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EFFECTIVENESS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DONOR LYMPHOCYTE INFUSION; DONOR SELECTION; FEMALE; HUMAN; IMMUNOCYTOMA; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SAFETY; STEM CELL; T LYMPHOCYTE; TRANSPLANTATION CONDITIONING; TREATMENT RESPONSE; ADOPTIVE IMMUNOTHERAPY; ALLOGRAFT; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTIONS; DONOR; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MYELODYSPLASTIC SYNDROMES; PROCEDURES; TRANSMISSION; TRANSPLANTATION; VIREMIA;

ALLOGRAFTS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE DEPLETION; MALE; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TISSUE DONORS; VIREMIA;

EID: 85013031108     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.16     Document Type: Article

References (29)

1. Passweg JR, Baldomero H, Peters C, Gaspar HB, Cesaro S, Dreger P, et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014; 49: 744-750
2. Zhou W, Longmate J, Lacey SF, Palmer JM, Gallez-Hawkins G, Thao L, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 2009; 113: 6465-6476
3. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116: 4360-4367
4. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044
5. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202: 379-386
6. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Löffler J, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916-3922
7. Stemberger C, Graef P, Odendahl M, Albrecht J, Dössinger G, Anderl F, et al. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood 2014; 124: 628-637
8. Peggs KS, Thomson K, Samuel E, Dyer G, Armoogum J, Chakraverty R, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011; 52: 49-57
9. Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, Schmidt B, et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002; 8: 631-637
10. Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, Odendahl M, et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirusspecific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011; 51: 591-599
11. Odendahl M, Grigoleit GU, Bönig H, Neuenhahn M, Albrecht J, Anderl F, et al. Clinical-scale isolation of ?minimally manipulated? cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease. Cytotherapy 2014; 16: 1245-1256
12. Stemberger C, Huster KM, Koffler M, Anderl F, Schiemann M, Wagner H, et al. A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity 2007; 27: 985-997
13. Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8 (+) central memory T cells. Immunity 2014; 41: 116-126
14. Buchholz VR, Flossdorf M, Hensel I, Kretschmer L, Weissbrich B, Gräf P, et al. Disparate individual fates compose robust CD8+ T cell immunity. Science 2013; 340: 630-635
15. Restifo NP. Big bang theory of stem-like T cells confirmed. Blood 2014; 124: 476-477
16. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123-1131
17. Uhlin M, Gertow J, Uzunel M, Okas M, Berglund S, Watz E, et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis 2012; 55: 1064-1073
18. Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M, et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010; 116: 5045-5049
19. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013; 121: 5113-5123
20. Dössinger G, Bunse M, Bet J, Albrecht J, Paszkiewicz PJ, Weissbrich B, et al. MHC multimer-guided and cell culture-independent isolation of functional T cell receptors from single cells facilitates TCR identification for immunotherapy. PLoS ONE 2013; 8: e61384
21. Koehne G, Hasan A, Doubrovina E, Prockop S, Tyler E, Wasilewski G, et al. Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia. Biol Blood Marrow Transplant 2015; 21: 1663-1678
22. Blyth E, Clancy L, Simms R, Ma CKK, Burgess J, Deo S, et al. Donor-derived CMVspecific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013; 121: 3745-3758
23. Peggs KS, Verfuerth S, Pizzey A, Chow S-LC, Thomson K, Mackinnon S. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis 2009; 49: 1851-1860
24. Feucht J, Opherk K, Lang P, Kayser S, Hartl L, Bethge W, et al. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 2015; 125: 1986-1994
25. Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, doubleblind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11: 284-292
26. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 2011; 121: 1673-1680
27. Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, et al. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest 2015; 125: 2677-2689
28. Stemberger C, Dreher S, Tschulik C, Piossek C, Bet J, Yamamoto TN, et al. Novel serial positive enrichment technology enables clinical multiparameter cell sorting. PLoS ONE 2012; 7: e35798
29. Eiz-Vesper B, Maecker-Kolhoff B, Blasczyk R. Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry. Front Immunol 2012; 3: 410